

INDEX

A

- Accessibility 4, 33-35, 59, 60, 62, 63, 65, 68, 73, 75-77, 82, 84, 90, 93-99, 103, 105-113, 116, 121, 123, 124, 126-128, 133-144, 149, 150, 153, 159, 160, 166, 168, 172, 173, 176, 181, 188
- Accessibility to recombination 76, 135, 144
- Acute lymphoblastic leukemia (ALL) 180, 182-187, 189, 190
- Allele 34, 38, 40, 53, 60, 63, 64, 66-69, 74, 75, 94, 104, 105, 109, 111-113, 118-123, 125-127, 133, 134, 136, 137, 139-144, 159, 160, 172-174, 183, 184, 189
- Allelic exclusion (AE) 34, 68, 104, 105, 111-113, 116, 117, 121, 125-128, 134, 136, 143, 144, 157, 160, 162, 166, 168, 171, 172, 176
- Alternative NHEJ *see* Nonhomologous end joining
- Antibody 60, 68, 73-76, 79, 83, 168, 171, 174
- Antigen receptor gene evolution 174
- Antisense transcription 64, 66, 69, 137, 138, 140
- Artemis 2, 3, 17, 18, 26, 27, 36, 37, 46, 48, 49, 51, 52, 170
- ATM 17, 34, 36, 39, 40, 52
- Atypical SCID 49

B

- Base-flipping 6-9, 11
- Basic helix-loop-helix (bHLH) 148, 187, 189
- B-cell 24, 26, 33-35, 40, 46-50, 54, 60, 62-64, 66-69, 74-77, 79, 94, 95, 104, 105, 108, 109, 111-113, 116, 122, 126, 133, 134, 136-144, 148-153, 159, 160, 168, 169, 171-174, 180, 182-186
- development 48, 60, 77, 105, 112, 133, 134, 136-139, 141-143, 150, 160, 169, 186
- fate commitment 138, 139
- fate specification 133, 134, 137, 138, 140

C

- Cancer 11, 49, 53, 54, 91, 128, 180, 181, 188
- Cell cycle 36, 38, 40, 52, 127, 134, 141, 142, 157, 158
- Cernunnos 2, 3, 17, 37, 46, 49, 51, 53, 54
- Cernunnos/XLF 53, 54
- c-Fos 10
- Chemokine 134, 142, 143
- Chromatin 33-36, 38, 40, 52, 59, 62, 63, 65-69, 73, 75, 76, 78-80, 90, 93-99, 103, 106-113, 121-124, 126-128, 133-141, 144, 149, 153, 159-162, 172-174, 181, 184, 186, 188
- accessibility 63, 68, 90, 93, 106, 107, 109-112, 121, 123, 124, 126-128, 135, 141, 149, 153, 181, 188
- immunoprecipitation (ChIP) 73, 76, 78, 79, 122, 124, 128, 152
- remodeling 59, 62, 63, 65, 69, 78, 80, 95, 99, 109, 110, 113, 123, 124, 149
- structure 35, 40, 62, 65, 67, 75, 76, 78, 79, 93, 95-98, 123, 124, 133-140, 144, 160
- Chromosomal translocation 16, 19, 21-23, 32, 54, 103, 189
- Chromosome territory 38-40, 63
- cis*-Regulatory element 119, 122-125, 128, 144, 150
- Cryptic RSS 34-36, 186
- CXCR4 134, 143
- CyclinA/Cdk2 158

D

- Disintegration 19, 21, 25
- DNA 1-6, 8-11, 16-27, 32-40, 46, 47, 49-54, 59, 60, 62, 68, 69, 74, 75, 77, 79, 80, 82, 84-86, 88, 89, 95, 96, 99, 103, 104, 107-109, 111, 116, 119, 123-128, 135, 136, 140, 142, 144, 148, 149, 152, 157-160, 162, 167-172, 174, 175, 181, 183, 185-188
- coding 18, 24, 26
- damage sensing 34, 39

footprinting 142, 149
 ligase IV 2, 3, 18, 27, 36, 37
 looping 68, 69, 125, 136, 140
 methylation 159
 repair 19, 32, 34, 37, 39, 46, 47, 50-53,
 104, 157, 158, 168, 188
 DNA-PK 36, 38, 51, 52, 54
 DNA-PKc 2, 3, 36, 37, 38, 51, 52
 D-region 66, 67

E

E2A 77-79, 94, 134, 137, 140, 142, 143,
 148-153, 186, 188, 189
 E12 148, 149
 E47 148-150
 E α 94, 97
 EBF 77, 78, 134, 137-141, 151, 153
 E-box site 148-150, 153
 Electrophoretic mobility shift assay (EMSA)
 3
 Enhancer 22, 35, 62, 63, 66, 68, 69, 79, 90,
 93, 94, 97, 98, 106, 109-112, 117-119,
 121-123, 126, 134, 136, 137, 140-144,
 148-150, 153, 159, 172, 175, 188
 Epigenetic control 73, 160
 Epigenetic regulation 108, 111, 159
 E-protein 148-153
 Ezh2 68, 69, 77, 134, 140

F

Fluorescence in situ hybridization (FISH)
 63, 64, 109, 111, 112, 126, 141, 144,
 188, 189
 Fluorescence resonance energy transfer
 (FRET) 5, 7

G

$\gamma\delta$ T cell 126, 152, 166, 168, 182, 184, 189,
 190
 Gene targeting 66, 94, 116, 117, 119, 120,
 122, 128, 137
 Genomic instability 16, 19, 33, 37, 53, 59,
 186
 Germline transcription 62, 63, 65, 66, 68, 69,
 76, 93-95, 97, 105, 106, 109-111, 123,
 124, 127, 135, 139, 142-144, 149, 160
 GTP 25

H

H3K4me3 27, 108, 158, 160-162
 H3R2me2s/K4me3 27
Haemophilus influenzae type b (*Hib*) 74, 75
 Heavy chain exclusion 169
 HEB 122, 148, 149-153, 188
 Histone acetylation 66, 68, 69, 76-78, 96,
 97-99, 137-139, 142, 143, 160
 Histone methylation 96, 98, 161
 Histone modification 35, 62, 63, 65, 66, 69,
 77, 80, 96, 99, 107-109, 112, 135, 137,
 139, 160, 161
 HMGB1 1-8, 10, 11, 33
 HMGB2 1
 Homologous recombination 38, 94, 97, 158
 Human primary immune deficiency 47

I

Id protein 148
 IgH enhancer 137, 150
 Igk enhancer 149, 153
 Ig/TCR 123, 126, 171, 180-182, 184-190
 IL-7R signaling 138, 140, 141
 Immunoglobulin (Ig) 1, 16, 22, 32-34, 39,
 46, 48, 59, 60, 68, 73-76, 98, 103-106,
 108, 109, 111, 116, 117, 123, 126, 127,
 133-136, 140-144, 148-150, 152, 153,
 159-161, 166-176, 180-182, 184-190,
 196
 Immunoglobulin (Ig) gene 75, 104, 105,
 109, 133, 135, 136, 144, 167, 168, 170,
 171, 174, 175, 187
 Immunoglobulin heavy chain (Igh) 39,
 59-69, 94, 99, 116, 122, 126, 140, 148,
 161, 169
 Inner nuclear membrane (INM) 109, 135,
 136, 140, 141, 144
 Intergenic transcription 62-66, 68, 69, 94,
 137
 IRF4 134, 136, 142, 143, 153
 IRF8 142
 I μ 'supergene' 63, 66, 68

J

J α segment 97, 98, 107

K

Ku 2, 3, 17, 18, 27, 36-39, 51

L

Leukemia 32, 33, 35, 39, 103, 180, 184, 185, 189

Locus 10, 19, 26, 35-37, 47, 51, 59-64, 66-69, 73, 75, 77-79, 82-90, 93-95, 97-99, 103-109, 111-113, 116-120, 122-128, 137-144, 149-151, 153, 157, 159, 161, 162, 169, 171-174, 182, 186, 188, 189

accessibility 35, 59, 60, 93, 106, 124, 142-144

compaction 140

contraction 35, 67-69, 79, 111, 113, 126, 128, 139-141, 169, 172-174

Lymphocyte 1, 10, 24, 32, 35, 39, 40, 46-51, 53, 54, 59, 60, 67, 68, 76, 82, 83, 85, 90, 103-106, 109, 111, 116, 117, 122, 126, 133, 144, 148, 149, 153, 157, 166, 168, 171-173, 176, 184

Lymphocyte development 1, 10, 32, 76, 103, 105, 109, 116, 133, 144, 148, 149

Lymphoid cancer 180, 181, 188

Lymphoid clonality 180, 181, 183, 184, 190

Lymphoid clonality analysis 180, 181, 183, 190

Lymphoma 26, 32, 33, 37, 39, 40, 54, 103, 180, 185, 188, 189, 190

M

Mechanism 1, 3, 5-7, 9, 11, 16, 24, 25, 27, 32-37, 39, 46, 59, 60, 62-64, 68, 69, 76, 79, 83, 90, 93, 95-99, 103-105, 107, 109-113, 116, 119, 123, 126, 128, 133-135, 137-144, 150, 151, 153, 157, 158, 162, 168, 171, 173, 174, 176, 186, 188, 190

Microhomology 37, 38

Mutagenesis 4, 8, 16, 19, 21, 24, 25, 52, 117

N

Noncoding RNA transcription 61-63, 69

Non-Hodgkin's lymphoma (NHL) 180, 185, 188

Nonhomologous end joining (NHEJ) 2, 3, 16-20, 22, 26, 27, 32-34, 36-38, 46, 51, 53, 54, 116, 158, 170

alternative 32, 37, 38

deficiency 37

Nuclear compartmentalization 109, 133, 134-136, 144

Nuclear lamina 135, 137, 139-141

Nuclear organization 67, 138

Nucleosome 4, 35, 62, 66, 76, 79, 95-97, 99, 107, 108, 110, 124, 134, 135, 138, 139, 153, 159, 160

Nucleosome phasing 159, 160

O

Oct-1 138, 139

Omenn syndrome (OS) 48-50

Oncogenesis 16, 19, 22, 24, 32-37, 117, 180, 181, 184-186, 188-190

P

Pathway 2, 3, 16, 18-24, 26, 27, 32, 34, 36-39, 46, 47, 122, 127, 133, 134, 138, 139, 142-144, 167, 168, 170

Pax5 10, 35, 67-69, 77, 79, 80, 94, 99, 134, 135, 139-142, 151, 153, 160

PDb1 95, 99

Pericentromeric heterochromatin 69, 112, 127, 135, 136, 142, 144

Peripheral T-lymphocyte 82, 85

PHD finger 35, 96, 99, 161, 162

Plant homeodomain 27, 35, 108, 158, 161

Post-cleavage complex 9

Pre-B-cell checkpoint 141

Pre-BCR signaling 141-143

Pre-T α 150, 151

Pre-Ta expression 151

Promoter 22, 32, 35, 60, 62-65, 79, 80, 90, 93-99, 106-111, 117-119, 121-123, 127, 135, 138-140, 149, 153, 159, 188, 189

Proteasomal degradation 158

Protein-DNA complex 3, 38

R

- Rag1 and Rag2 leaky mutation 48
 Rearrangement 10, 11, 24, 32-36, 40, 46-49, 69, 73-80, 82-90, 94, 95, 97, 98, 104, 105, 107, 109-112, 116-119, 121, 122, 125-127, 133, 134, 137-144, 148-153, 157, 159, 160, 166, 168-176, 180-186, 188-190
 Recombinase 6, 16, 17, 33-37, 60, 63, 68, 79, 93, 94, 97, 99, 103-109, 111-113, 116, 117, 119, 123, 128, 134, 135, 137-139, 141, 143, 149, 157, 159-162, 166, 167, 176, 180, 181, 184-190
 Recombination 1-6, 8-11, 16-20, 22, 24, 27, 32-40, 46-48, 50-54, 59-69, 73-79, 82-85, 87, 90, 93-95, 97-99, 103-113, 116, 117, 119, 121-128, 133-144, 148-153, 157-162, 166-176, 180, 186
 Recombination activating gene (RAG) 1-11, 16-27, 32-40, 48, 59, 60, 76, 79, 80, 94, 95, 99, 104-106, 108, 113, 123, 134, 135, 137, 140-143, 148-151, 157-162, 166-168, 170-174, 176, 186, 188, 190
 expression 149, 151
 transposon 167
 Recombination activating gene 1 (RAG-1) 1, 3-9, 11, 16-21, 24-27, 33, 35, 37-39, 46-51, 60, 77, 79, 104, 116, 117, 122, 123, 133-135, 139, 149, 150, 157, 159, 167, 168, 186, 188-190
 Recombination activating gene 2 (RAG-2) 1, 3-5, 7, 9, 10, 16, 17, 19, 24, 25, 27, 33, 35-39, 46-51, 60, 77, 79, 99, 104, 108, 116, 127, 128, 133-135, 139, 149, 150, 157-159, 161, 162, 167, 168
 C-terminus 24, 25, 27, 99
 deficiency 39, 47, 48
 Recombination signal sequence (RSS) 1-11, 16-21, 23, 24, 26, 33-36, 46, 59, 60, 73-76, 78-80, 93, 94, 95, 98, 99, 104, 105, 108, 110, 111, 116-121, 124, 126, 128, 134, 135, 137-140, 149, 157, 159, 160, 166-170, 175, 186, 188
 Recombination substrate 9, 51, 74, 75, 94
 Regulation 16, 24, 25, 27, 32-34, 40, 52, 59, 60, 62, 64, 85, 90, 93, 97, 98, 103, 104, 107-109, 111-113, 116, 117, 123, 126, 128, 136, 141-143, 148-153, 157-159, 161, 162, 168, 189

- RNA-FISH 63, 64
 RNA polymerase II 63
 ROR γ t 151, 153
 RS-SCID 47, 49, 51-54

S

- SCID with microcephaly 49
 Secondary IgL rearrangement 150
 Severe combined immune deficiency (SCID) 37, 46-54
 Size and diversity T cell receptor repertoire 90
 Skp2-SCF 158
 Stat5 94, 139, 141, 143
 Surrogate light chain 104, 134, 150, 151
 Synaptic complex 1-7, 9-11, 33, 36

T

- Target capture 19, 20, 24-27
 Target site 19, 21, 24, 25, 27, 35, 158
 T-B-SCID 47-50
 T-cell receptor (TCR) 1, 10, 16, 32-34, 39, 46, 48-50, 59, 60, 74-76, 82-85, 87, 90, 98, 103-106, 108, 109, 111, 116, 118, 126, 127, 148-153, 166, 168, 171, 172, 180-190
 gene 16, 32, 75, 90, 103-106, 149, 150, 153, 168, 187
 loci 34, 50, 60, 74, 76, 98, 106, 108, 109, 148-150, 152, 153, 181, 185, 186, 189
 TCR α 104, 106, 107, 111, 149-151, 153
 TCR β 10, 34, 36, 76, 83, 94, 95, 104-106, 109-113, 117, 119-121, 126, 127, 149-151, 159, 160, 172, 182, 184, 185, 188-190
 Tcra 60, 66, 69, 97, 98, 117, 121, 126
 TCRAD locus 82, 83-86, 88, 89
 Tcrb 60, 69, 94, 95, 99, 116-119, 121-128
 TdT expression 150
 T early α (TEA) 90, 97-99
 Thymocyte 34, 48-50, 94, 95, 104, 108-112, 116, 119, 123-127, 151, 153, 158, 174
 Transcription 10, 11, 33, 35, 61-69, 73, 76-80, 84, 90, 93-99, 105-107, 109-113, 117, 119-124, 127, 133-144, 148-151, 159, 160, 162, 174

Transcriptional elongation 96-99
Transcriptional interference 98, 128
Transcriptional regulation 153
Transcription factor (TF) 10, 11, 35, 62, 67,
73, 77-80, 94, 96, 110, 119, 122, 123,
127, 133-144, 148, 151, 160
Transcription factory 68
Transcription terminator 97, 98
Transposition 8, 11, 16, 18-27
Transposon 6, 24, 27, 167

V

Variation 33, 73, 74, 79, 80, 87, 117, 159,
171
V(D)J 16-19, 22, 24, 26, 27, 32-40, 46-54,
59-62, 64-67, 69, 75, 79, 83, 93, 94, 97,
99, 103-109, 111-113, 116, 117, 119,
122-125, 126, 128, 134, 135, 138, 144,
148-153, 157-162, 166-168, 170-173,
176, 180, 181, 185, 186, 188, 190

V(D)J rearrangement 2, 10, 11, 75, 122,
172, 173, 176, 181, 185, 188
V(D)J recombination 1-6, 8-11, 16-19, 22,
24, 27, 32-40, 46-48, 50-54, 59-62, 64-
67, 69, 79, 83, 93, 94, 97, 99, 103-109,
111-113, 116, 117, 123-126, 128, 134,
144, 148-153, 157-162, 166, 168, 170,
171, 173, 176, 180
V_H gene 10, 60, 62-65, 67-69, 73-75, 77, 79,
94, 112, 134-141, 169, 172, 173
V_K gene 94, 111
V region 60, 63, 64, 66-69, 82, 84, 166, 171

X

XRCC4 2, 3, 17, 18, 26, 27, 36-38, 51, 53,
54

Y

YY1 67-69, 79, 134, 136, 140, 141